Tirzepatide with buprenorphine for opioid use disorder
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Mental health clinical trials.
This study tests whether adding tirzepatide, a medication used for weight and blood sugar, to buprenorphine treatment helps people with opioid use disorder. It aims to see if the combination improves outcomes compared to buprenorphine alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have moderate to severe opioid use disorder.
- You must have started buprenorphine treatment recently (within the last 7 to 80 days) and be taking at least 8 mg per day.
- You must be willing to come to weekly study visits for 6 months and take either tirzepatide or a placebo (inactive shot).
- You must not be pregnant or breastfeeding and must agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called Brenipatide for people with opioid use disorder who are already taking buprenorphine but still occasionally use non-prescribed opioids. It aims to see if the study drug can help reduce opioid use.
This study compares two medications, methadone and buprenorphine, to see which helps people stay in treatment for opioid use disorder. You may be eligible if you are starting a new treatment episode.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This trial tests if tezampanel can help relieve withdrawal symptoms in people with opioid use disorder who are seeking treatment. Participants must already be in an outpatient addiction program.
This study tests whether a medication called tirzepatide (a once-weekly injection) can help people reduce their alcohol consumption. It is for people who drink heavily, have a high BMI, and are actively seeking help to drink less.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.